Zhang Qiang, Bhojani Mahaveer S, Ben-Josef Edgar, Spalding Aaron C, Kuick Rork, Sun Yi, Morgan Meredith A
Department of Radiation Oncology, University of Michigan Medical School, USA.
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
J Carcinog Mutagen. 2013 Aug 16;4(3):147. doi: 10.4172/2157-2518.1000147.
Pancreatic cancer is a highly lethal disease with a poor prognosis characterized by local and systemic disease progression. Both radiation and chemotherapy play important roles in the management of this disease. However, in order to improve standard therapy many molecularly targeted agents are being developed. Glycogen synthase kinase 3β (GSK3β) participates in a multitude of cellular processes and is a newly proposed therapeutic target in pancreatic cancer. This review will discuss both the oncogenic and tumor suppressor functions of GSK3β in pancreatic cancer with an emphasis on the roles of GSK3β in tumor cell survival and sensitivity to radiation and chemotherapy.
胰腺癌是一种高度致命的疾病，预后较差，其特征是局部和全身疾病进展。放疗和化疗在这种疾病的治疗中都起着重要作用。然而，为了改进标准疗法，许多分子靶向药物正在研发中。糖原合酶激酶3β（GSK3β）参与多种细胞过程，是胰腺癌中一个新提出的治疗靶点。本综述将讨论GSK3β在胰腺癌中的致癌和抑癌功能，重点是GSK3β在肿瘤细胞存活以及对放疗和化疗敏感性方面的作用。
